Neurological Sciences

, Volume 31, Issue 3, pp 253–257 | Cite as

Interleukin-1B and interleukin-1 receptor antagonist gene polymorphisms in Greek multiple sclerosis (MS) patients with bout-onset MS

  • Konstantinos Aggelakis
  • Fani Zacharaki
  • Efthimios Dardiotis
  • Georgia Xiromerisiou
  • Vana Tsimourtou
  • Styliani Ralli
  • Maria Gkaraveli
  • Dimitris Bourpoulas
  • Paraskevi Rodopoulou
  • Alexandros Papadimitriou
  • Georgios Hadjigeorgiou
Original Article


We investigated the association of specific polymorphisms of the interleukin IL-1b (AvaI −511 and TaqI +3,953) and IL-1 receptor antagonist (IL-1RN) (a variable number of tandem repeats; VNTR) genes with both the susceptibility to and the clinical characteristics in Greek multiple sclerosis (MS) patients cohort with bout-onset. Genotypes were determined from 351 patients with clinically definite MS and 375 age- and sex-matched healthy controls. Our results showed no significant differences in the distribution of these polymorphisms between MS patients and controls. Furthermore, stratification for clinical characteristics, such as age at disease onset, clinical course, sex, and severity did not provide significant differences between patients and controls. Together, our findings suggest that IL-1B and IL-1RN gene polymorphisms may not be relevant to the susceptibility to MS or the clinical characteristics of Greek MS patients.


Multiple sclerosis Interleukin Association Polymorphism Gene 



We would like to thank Elias Zintzaras, Assoc. Prof. Biomathematics, Dept of Biomathematics, Faculty of Medicine, University of Thessaly, Greece for his helpful suggestion in protocol design and analysis of data.


  1. 1.
    Lassmann H, Bruck W, Lucchinetti CF (2007) The immunopathology of multiple sclerosis: an overview. Brain Pathol 17:210–218CrossRefPubMedGoogle Scholar
  2. 2.
    Marrie RA (2004) Environmental risk factors in multiple sclerosis aetiology. Lancet Neurol 3:709–718CrossRefPubMedGoogle Scholar
  3. 3.
    Poser CM (2006) The multiple sclerosis trait and the development of multiple sclerosis: genetic vulnerability and environmental effect. Clin Neurol Neurosurg 108:227–233CrossRefPubMedGoogle Scholar
  4. 4.
    Patterson D, Jones C, Hart I et al (1993) The human interleukin-1 receptor antagonist (IL1RN) gene is located in the chromosome 2q14 region. Genomics 15:173–176CrossRefPubMedGoogle Scholar
  5. 5.
    Nicklin MJ, Weith A, Duff GW (1994) A physical map of the region encompassing the human interleukin-1 alpha, interleukin-1β, and interleukin-1 receptor antagonist genes. Genomics 19:382–384CrossRefPubMedGoogle Scholar
  6. 6.
    Dinarello CA, Wolff SM (1993) The role of interleukin-1 in disease. N Engl J Med 328:106–113CrossRefPubMedGoogle Scholar
  7. 7.
    Arend WP (1991) Interleukin 1 receptor antagonist: a new member of the interleukin 1 family. J Clin Invest 88:1445–1451CrossRefPubMedGoogle Scholar
  8. 8.
    Nicoletti F, Patti F, DiMarco R et al (1996) Circulating serum levels of IL-1ra in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increased either during exacerbations or in response to IFN-β treatment. Cytokine 8:395–400CrossRefPubMedGoogle Scholar
  9. 9.
    di Giovine FS, Takhsh E, Blakemore AI, Duff GW (1992) Single base polymorphism at −511 in the human interleukin-1β gene (IL1β). Hum Mol Genet 1:450CrossRefPubMedGoogle Scholar
  10. 10.
    Pociot F, Molvig J, Wogensen L, Worsaae H, Nerup J (1992) A TaqI polymorphism in the human interleukin-1β (IL-1β) gene correlates with IL-1β secretion in vitro. Eur J Clin Invest 22:396–402CrossRefPubMedGoogle Scholar
  11. 11.
    Tarlow JK, Blakemore AI, Lennard A et al (1993) Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 91:403–404CrossRefPubMedGoogle Scholar
  12. 12.
    Arend WP (2002) The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev 13:323–340CrossRefPubMedGoogle Scholar
  13. 13.
    McDonald WI, Compston A, Edan G et al (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121–127CrossRefPubMedGoogle Scholar
  14. 14.
    Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452PubMedGoogle Scholar
  15. 15.
    Roxburgh RH, Seaman SR, Masterman T et al (2005) Multiple sclerosis severity score: using disability and disease duration to rate disease severity. Neurology 64:1144–1151PubMedGoogle Scholar
  16. 16.
    Kantarci OH, de Andrade M, Weinshenker BG (2002) Identifying disease modifying genes in multiple sclerosis. J Neuroimmunol 123:144–159CrossRefPubMedGoogle Scholar
  17. 17.
    Hadjigeorgiou GM, Stefanidis I, Dardiotis E et al (2007) Low RLS prevalence and awareness in central Greece: an epidemiological survey. Eur J Neurol 14:1275–1280CrossRefPubMedGoogle Scholar
  18. 18.
    Hodge PJ, Riggio MP, Kinane DF (2001) Failure to detect an association with IL1 genotypes in European Caucasians with generalised early onset periodontitis. J Clin Periodontol 28:430–436CrossRefPubMedGoogle Scholar
  19. 19.
    Hafler DA, Compston A, Sawcer S et al (2007) Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 357:851–862CrossRefPubMedGoogle Scholar
  20. 20.
    Zintzaras E, Lau J (2008) Trends in meta-analysis of genetic association studies. J Hum Genet 53:1–9CrossRefPubMedGoogle Scholar
  21. 21.
    Zintzaras E, Lau J (2008) Synthesis of genetic association studies for pertinent gene–disease associations requires appropriate methodological and statistical approaches. J Clin Epidemiol 61:634–645CrossRefPubMedGoogle Scholar
  22. 22.
    Kitsios GD, Zintzaras E (2009) Genomic convergence of genome-wide investigations for complex traits. Ann Hum Genet 75:514–519. doi: 10.1111/j.1469-1809.2009.00533.x CrossRefGoogle Scholar
  23. 23.
    Kitsios GD, Zintzaras E (2009) Genome-wide association studies: hypothesis-“free” or “engaged”? Transl Res 154:161–164CrossRefPubMedGoogle Scholar
  24. 24.
    Sciacca FL, Ferri C, Vandenbroeck K et al (1999) Relevance of interleukin 1 receptor antagonist intron 2 polymorphism in Italian MS patients. Neurology 52:1896–1898PubMedGoogle Scholar
  25. 25.
    de la Concha EG, Arroyo R, Crusius JB et al (1997) Combined effect of HLA-DRB1*1501 and interleukin-1 receptor antagonist gene allele 2 in susceptibility to relapsing/remitting multiple sclerosis. J Neuroimmunol 80:172–178CrossRefGoogle Scholar
  26. 26.
    Mann CL, Davies MB, Stevenson VL et al (2002) Interleukin 1 genotypes in multiple sclerosis and relationship to disease severity. J Neuroimmunol 129:197–204CrossRefPubMedGoogle Scholar
  27. 27.
    Luomala M, Lehtimaki T, Elovaara I et al (2001) A study of interleukin-1 cluster genes in susceptibility to and severity of multiple sclerosis. J Neurol Sci 185:123–127CrossRefPubMedGoogle Scholar
  28. 28.
    Crusius JB, Pena AS, Van Oosten BW et al (1995) Interleukin-1 receptor antagonist gene polymorphism and multiple sclerosis. Lancet 346:979CrossRefPubMedGoogle Scholar
  29. 29.
    Dincic E, Zivkovic M, Stankovic A et al (2006) Association of polymorphisms in CTLA-4, IL-1ra and IL-1β genes with multiple sclerosis in Serbian population. J Neuroimmunol 177:146–150CrossRefPubMedGoogle Scholar
  30. 30.
    Schrijver HM, Crusius JB, Uitdehaag BM et al (1999) Association of interleukin-1β and interleukin-1 receptor antagonist genes with disease severity in MS. Neurology 52:595–599PubMedGoogle Scholar
  31. 31.
    Feakes R, Sawcer S, Broadley S et al (2000) Interleukin 1 receptor antagonist (IL-1ra) in multiple sclerosis. J Neuroimmunol 105:96–101CrossRefPubMedGoogle Scholar
  32. 32.
    Kantarci OH, Atkinson EJ, Hebrink DD, McMurray CT, Weinshenker BG (2000) Association of two variants in IL-1β and IL-1 receptor antagonist genes with multiple sclerosis. J Neuroimmunol 106:220–227CrossRefPubMedGoogle Scholar
  33. 33.
    Ferri C, Sciacca FL, Grimaldi LE et al (2000) Lack of association between IL-1A and IL-1B promoter polymorphisms and multiple sclerosis. J Neurol Neurosurg Psychiatry 69:564–565CrossRefPubMedGoogle Scholar
  34. 34.
    Cardon LR, Bell JI (2001) Association study designs for complex diseases. Nat Rev Genet 2:91–99CrossRefPubMedGoogle Scholar
  35. 35.
    Kira J, Kanai T, Nishimura Y et al (1996) Western versus Asian types of multiple sclerosis: immunogenetically and clinically distinct disorders. Ann Neurol 40:569–574CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Konstantinos Aggelakis
    • 1
    • 2
  • Fani Zacharaki
    • 1
  • Efthimios Dardiotis
    • 1
    • 2
  • Georgia Xiromerisiou
    • 2
  • Vana Tsimourtou
    • 1
  • Styliani Ralli
    • 1
  • Maria Gkaraveli
    • 1
  • Dimitris Bourpoulas
    • 2
  • Paraskevi Rodopoulou
    • 3
  • Alexandros Papadimitriou
    • 1
  • Georgios Hadjigeorgiou
    • 1
    • 2
  1. 1.Department of Neurology, Faculty of MedicineUniversity of ThessalyLarissaGreece
  2. 2.Institute of Biomedical Research and TechnologyLarissaGreece
  3. 3.Department of Biomathematics, Faculty of MedicineUniversity of ThessalyLarissaGreece

Personalised recommendations